Two cases of stage IV acinar carcinoma of the
pancreas are presented. The two patients were treated with
several lines of chemotherapies active against colon cancer. At
last-line, both patients received panitumumab monotherapy.
We describe the tumour response to the different therapies.
Our findings demonstrate that panitumumab produces objective responses when used as third-line treatment in the therapy
of patients with acinar cell carcinoma of the pancreas. Thus,
we propose the consideration of the use of panitumumab in
early lines of treatment.
